The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDGL | +35.85% | +279.95% | +30.6% | +4,096% |
| S&P | +16.53% | +80.89% | +12.59% | +214% |
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $321.08M | 210.8% |
| Gross Profit | $296.24M | 197.7% |
| Gross Margin | 92.26% | -4.1% |
| Market Cap | $13.23B | 96.5% |
| Market Cap / Employee | $14.45M | 0.0% |
| Employees | 915 | 73.3% |
| Net Income | -$58,575.00K | 1.4% |
| EBITDA | -$59,217.00K | 11.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $203.78M | 94.0% |
| Accounts Receivable | $134.48M | 149.9% |
| Inventory | 74.8 | 119.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $346.61M | 192.3% |
| Short Term Debt | $1.02M | 3.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.05% | 30.3% |
| Return On Invested Capital | -90.37% | -6.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$133,070.00K | -27.1% |
| Operating Free Cash Flow | -$133,460.00K | -27.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.66 | 9.45 | 14.64 | 21.13 | 144.04% |
| Price to Sales | 23.06 | 13.04 | 13.92 | 13.87 | -63.07% |
| Price to Tangible Book Value | 9.72 | 9.51 | 14.74 | 21.39 | 145.46% |
| Enterprise Value to EBITDA | -83.48 | -129.05 | -84.00 | -213.68 | 139.09% |
| Return on Equity | -50.2% | -36.3% | -41.2% | -42.5% | -47.12% |
| Total Debt | $119.77M | $123.95M | $346.40M | $347.63M | 190.73% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
